Glioblastoma, IDH-wildtype Clinical Trial
Official title:
Phase 2 Study of Ropidoxuridine as a Radiation Sensitizing Agent During Radiotherapy in Patients With Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
This is a randomized, open-label, phase 2 study evaluating the safety and efficacy of oral ropidoxuridine as a radiation-sensitizing agent in patients with newly diagnosed wild-type isocitrate dehydrogenase glioblastoma with an unmethylated O6-methylguanine-DNA methyltransferase promoter, undergoing standard 60 Gy radiotherapy.
Status | Not yet recruiting |
Enrollment | 54 |
Est. completion date | February 2027 |
Est. primary completion date | August 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Written informed consent form signed and dated by patient or legally authorized representative according to local guidelines, prior to the performance of any study-specific procedures, sampling, or analyses. Participants with impaired decision-making capacity must have a close caregiver or legally authorized representative present. - Histologically confirmed supratentorial glioblastoma isocitrate dehydrogenase (IDH) wild-type classification (2021 World Health Organization Classification of Tumours, 5th Edition, Volume 6) with unmethylated O6-methylguanine-DNA-methyltransferase (MGMT) promoter (defined as MGMT methylation status =20% by pyrosequencing, and no prior radiation, electric field, or systemic therapy. Glucocorticoid therapy for symptom control is allowed. - Patients should, in the opinion of the investigator, be candidates for 60 Gy radiotherapy in 2 Gy fractions over 6 weeks, per standard of care. Hypofractionated radiotherapy schedules (e.g., 36 Gy in 3 Gy fractions) are not allowed. - Eastern Cooperative Oncology Group performance status of 0, 1 or 2. - Adequate renal, liver and bone marrow function: - Hemoglobin >9.0 g/dL - Absolute neutrophil count >1.5 × 10^9/L - Platelet count >100 × 10^9/L - Total bilirubin =1.5 × upper limit of normal (ULN), unless due to documented Gilbert's disease (=3 × ULN) - Aspartate aminotransferase / alanine aminotransferase =4×ULN - Creatinine clearance =60 mL/min calculated as per Cockcroft-Gault equation. - Life expectancy =12 weeks. - Have recovered from the immediate post-operative period and is maintained on a stable corticosteroid regimen (no increase for 5 days) prior to initiation of study treatment. - Female patients, of childbearing potential, must have a negative serum pregnancy test within 7 days prior to taking study medication and agree to use at least one highly effective form of contraception during study treatment and for at least 120 days after the last dose of study treatment. - Male patients must agree to use an adequate method of contraception from enrollment through 120 days after the last dose of study treatment. Exclusion Criteria: - Any prior treatment for glioblastoma, including chemotherapy, immunotherapy, targeted therapy or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, lymphokine-activated killer cell therapy or gene therapy), or radiotherapy. Glucocorticoid therapy is permitted. - Second primary malignancy expected to require active treatment within a 6-month period (except basal cell or early-stage squamous cell carcinoma of the skin that may be excised). Patients who had another malignancy in the past but have been free of active disease for more than 1 year, are eligible even if under active surveillance, at the discretion of the Investigator. Adjuvant anti hormonal treatment for prior breast or prostate cancer is allowed, but no other concomitant anticancer treatment. - Any investigational therapy (for any concomitant condition) within 28 days or within 5 half-lives of study entry (whichever is shorter). - Use of acid-reducing agents including proton pump inhibitors and histamine-2 blockers. - Inability to comply with protocol or study procedures. - Women who are pregnant or breastfeeding. - Inability to swallow oral medication or gastrointestinal disorder expected to severely affect drug absorption (e.g., short bowel syndrome). - Ongoing bacterial, viral, or fungal infection requiring systemic therapy. Prophylactic therapy is allowed. Patients with a history of Human Immunodeficiency Virus, Hepatitis B virus, Hepatitis C virus infection are allowed if treated with effective anti-viral therapy that results in undetectable viral load. - Any medical condition, which in the opinion of the Investigator, places the patient at an unacceptably high risk for toxicities, or makes the patient unsuitable for study participation. |
Country | Name | City | State |
---|---|---|---|
United States | University of Virginia | Charlottesville | Virginia |
United States | John Theurer Cancer Center at the Hackensack University Medical Center | Hackensack | New Jersey |
United States | Sylvester Comprehensive Cancer Center | Miami | Florida |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | Allegheny General Hospital | Pittsburgh | Pennsylvania |
United States | Lombardi Comprehensive Cancer Center at Georgetown University | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Shuttle Pharmaceuticals, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of patients treated with oral ropidoxuridine at dose levels of 960 and 1200 mg once daily, with treatment-related adverse events assessed by CTCAE v5.0. | From the first day of treatment start until 30 days after treatment completion | ||
Primary | adiographic response rate, disease control rate, best overall response, and duration of overall response in patients treated with oral ropidoxuridine at 960 and 1200 mg daily doses, assessed using the Response Assessment in Neuro-Oncology criteria. | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months. | ||
Primary | Maximum plasma concentration for orally administered ropidoxuridine, at dose levels of 960 and 1200 mg once daily. | he first 36 days of treatment. | ||
Primary | Trough plasma concentration of orally administered ropidoxuridine, at dose levels of 960 and 1200 mg once daily | The first 36 days of treatment. | ||
Primary | Time to maximum plasma concentration for orally administered ropidoxuridine, at dose levels of 960 and 1200 mg once daily. | The first 36 days of treatment. | ||
Primary | Area under the curve for orally administered ropidoxuridine, at dose levels of 960 and 1200 mg once daily. | The first 36 days of treatment. | ||
Primary | Half-life for orally administered ropidoxuridine, at dose levels of 960 and 1200 mg once daily. | The first 36 days of treatment. | ||
Secondary | Overall survival at 12 months | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months. | ||
Secondary | Radiographic Response Rate | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months. | ||
Secondary | Disease Control Rate | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months. | ||
Secondary | Best Overall Response | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months. | ||
Secondary | Duration of Response | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months. | ||
Secondary | Overall Survival | From date of randomization until the date of death from any cause, whichever came first, assessed up to 100 months. | ||
Secondary | Progression-Free Survival | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months. | ||
Secondary | Six-Month Progression-Free Survival | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months. | ||
Secondary | Fraction of patients with tumor progression outside of the treatment area. | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months. | ||
Secondary | Quantification of 9 relevant neurologic domains based on the NANO scale. | The Neurologic Assessment in Neuro-Oncology (NANO) scale is a clinical tool used to measure neurological function in patients with brain tumors. The scale can range from a score of 0 to a maximum score that depends on the severity and number of deficits. Higher scores on the NANO scale typically indicate a greater degree of neurological impairment. | Measured from the time of study enrollment until 28 (±7) days following the completion of study treatment. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05941234 -
Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma
|
N/A | |
Recruiting |
NCT04528680 -
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06047379 -
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
|
Phase 1/Phase 2 | |
Recruiting |
NCT06160596 -
Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis
|
||
Recruiting |
NCT05879250 -
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
|
Phase 2 | |
Not yet recruiting |
NCT04945148 -
Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide
|
Phase 2 | |
Not yet recruiting |
NCT05842746 -
Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma
|
Phase 2 | |
Not yet recruiting |
NCT06419946 -
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
|
Phase 3 | |
Completed |
NCT03434262 -
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
|
Phase 1 | |
Recruiting |
NCT06418113 -
Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma
|
Phase 1 | |
Recruiting |
NCT05326334 -
THERApeutic Outcomes Related to Gut microBIOME in Glioblastoma (GBM) Patients Receiving Chemo-radiation (THERABIOME-GBM)
|
||
Recruiting |
NCT05375318 -
BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels
|
||
Recruiting |
NCT06095375 -
Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients
|
Phase 1 | |
Recruiting |
NCT05879367 -
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma
|
Phase 1 | |
Recruiting |
NCT05759195 -
Biomolecular Analysis for Predicting Response to Regorafenib
|
N/A | |
Recruiting |
NCT06146738 -
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
|
||
Recruiting |
NCT06283927 -
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
|
||
Recruiting |
NCT06273176 -
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
|
||
Recruiting |
NCT06146725 -
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
|
||
Recruiting |
NCT06118723 -
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
|